Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) Shares Shorted: Short Interest Up 69.8% in October

Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT – Get Free Report) saw a significant increase in short interest in October. As of October 30th, there was short interest totaling 152,917 shares, an increase of 69.8% from the October 15th total of 90,040 shares. Currently, 6.8% of the shares of the company are sold short. Based on an average trading volume of 6,760,367 shares, the short-interest ratio is currently 0.0 days.

Lakewood-Amedex Biotherapeutics Price Performance

Shares of LABT stock traded down $0.06 during trading hours on Monday, hitting $0.22. 789,942 shares of the company were exchanged, compared to its average volume of 7,484,873. The company’s fifty day moving average price is $0.99. Lakewood-Amedex Biotherapeutics has a 52-week low of $0.17 and a 52-week high of $98.20. The firm has a market cap of $519,978.00 and a PE ratio of -0.05.

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT – Get Free Report) last posted its quarterly earnings data on Friday, August 14th. The company reported ($2.75) EPS for the quarter. Research analysts forecast that Lakewood-Amedex Biotherapeutics will post 4.96 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

LABT has been the subject of a number of research analyst reports. HC Wainwright initiated coverage on Lakewood-Amedex Biotherapeutics in a research report on Wednesday, October 28th. They set a “buy” rating for the company. Wall Street Zen cut Lakewood-Amedex Biotherapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, November 7th. Finally, Weiss Ratings raised Lakewood-Amedex Biotherapeutics from a “sell (e-)” rating to a “sell (e)” rating in a research report on Friday, October 2nd. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold”.

View Our Latest Analysis on LABT

About Lakewood-Amedex Biotherapeutics

(Get Free Report)

Lakewood-Amedex Biotherapeutics is a biotechnology company focused on developing treatments for bacterial infections, including infections caused by drug-resistant pathogens. Its research centers on bisphosphocins, a class of investigational antimicrobial compounds. The company’s activities are primarily research and development; its investigational compounds should not be confused with approved medicines or commercially available products. Publicly available information about its specific product pipeline, operating geographies and leadership is limited.

See Also

Receive News & Ratings for Lakewood-Amedex Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lakewood-Amedex Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.